You are here

hemophilia A

BioMarin tries to get hemophilia gene therapy back on track with positive data

BioMarin tries to get hemophilia gene therapy back on track with positive data

BioPharma Dive

clinical trials

Flag link:

#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout

#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout

Endpoints

Flag link:

How BioMarin Beat Expectations in Q3

How BioMarin Beat Expectations in Q3

Motley Fool

Flag link:

Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment SB-525

Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment SB-525

Drugs.com

Sangamo Therapeutics

clinical trials

giroctocogene fitelparvovec

Flag link:

Sanofi's hemophilia drug comes into focus as delays hit a key competitor

Sanofi's hemophilia drug comes into focus as delays hit a key competitor

BioPharma Dive

Flag link:

Is valrox dead?

Is valrox dead?

EP Vantage

Flag link:

FDA gets out its red pen again, rejecting BioMarin's gene therapy valrox amid durability worries

FDA gets out its red pen again, rejecting BioMarin's gene therapy valrox amid durability worries

Fierce Biotech

Flag link:

Roche targets 2021 start for hemophilia A gene therapy phase 3 as optimization effort drags on

Roche targets 2021 start for hemophilia A gene therapy phase 3 as optimization effort drags on

Fierce Biotech

Spark Therapeutics

Flag link:

Pfizer, Sangamo flesh out hemophilia gene therapy data ahead of phase 3

Pfizer, Sangamo flesh out hemophilia gene therapy data ahead of phase 3

Fierce Biotech

Sangamo BioSciences

clinical trials

giroctocogene fitelparvovec

Flag link:

BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment

BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment

BioSpace

clinical trials

valoctocogene roxaparvovec

Flag link:

BioMarin gene therapy shows sustained benefit in hemophilia A study

BioMarin gene therapy shows sustained benefit in hemophilia A study

Seeking Alpha

clinical trials

valoctocogene roxaparvovec

Flag link:

Regeneron to expand development deal with Intellia Therapeutics

Regeneron to expand development deal with Intellia Therapeutics

Marketwatch

Intellia Therapeutics

drug development

Flag link:

BioMarin's Novel Treatment Promises to Disrupt Competitors

BioMarin's Novel Treatment Promises to Disrupt Competitors

Motley Fool

Flag link:

FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review

FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review

Motley Fool

priority review

Flag link:

Novimmune unit nabs Takeda milestone payment for hemophilia work

Novimmune unit nabs Takeda milestone payment for hemophilia work

Fierce Biotech

Light Chain Bioscience

Flag link:

Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World

Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World

Forbes

Flag link:

Takeda Eyes 12 New Drug Approvals by 2024, Hemophilia Gene Therapy May Not be a Competitor

Takeda Eyes 12 New Drug Approvals by 2024, Hemophilia Gene Therapy May Not be a Competitor

BioSpace

Flag link:

Generation Bio grabs a $110M round to ramp up work on next-gen gene therapies

Generation Bio grabs a $110M round to ramp up work on next-gen gene therapies

Fierce Biotech

phenylketonuria

Flag link:

Value-based pricing for gene therapy? Maybe not ready for hemophilia

Value-based pricing for gene therapy? Maybe not ready for hemophilia

Biopharma Dive

valoctocogene roxaparvovec

Flag link:

Sigilon Therapeutics approaches the clinic

Sigilon Therapeutics approaches the clinic

EP Vantage

Flag link:

Pages